Regencell Bioscience Holdings Limited RGC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -226.49% | -244.82% | -280.27% | -473.63% | -- |
| Total Depreciation and Amortization | 3.00% | 76.88% | 637.07% | 1,395.37% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,328.81% | 3,625.86% | 2,600.61% | 2,660.82% | -- |
| Change in Net Operating Assets | 2,021.28% | 2,121.28% | -- | -- | -- |
| Cash from Operations | -147.16% | -142.81% | -134.85% | -317.60% | -- |
| Capital Expenditure | -- | 0.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -11.80% | 145.31% | 1,890.38% | 3,001.10% | -- |
| Cash from Investing | -6.78% | 152.86% | 1,830.59% | 2,881.53% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 116.40% | -160.94% | -340.38% | -521.14% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,271.38% | 751.41% | 156.38% | 117.23% | -- |